Eli Lilly Fights Back Against Digital Impersonation Amid Global Obesity Drug Boom
Aug/08/2025
As competition intensifies in the weight-loss drug market, Eli Lilly defends its Mounjaro brand from online exploitation. On May 12, 2025, the company filed a complaint with the WIPO Arbitration and Mediation Center, targeting the domain name <mounjarotrick.online>, which was registered and used to promote an unverified product called "Mounjaro Natural Trick". Lilly argued — and the WIPO panel agreed on July 16 — that the domain name was confusingly similar to its registered trademark and had been used to trading off the brand equity of its GLP-1-based blockbuster drug. This decision comes at a time when demand for obesity treatments like Mounjaro and Zepbound has surged globally, with companies racing to develop oral alternatives to injectable therapies. Although Lilly recently suffered a market setback with lower-than-expected weight-loss results from its experimental pill orforglipron, its GLP-1 franchise remains one of the most formidable in the pharmaceutical industry. The protection of its digital footprint is increasingly critical, especially as counterfeit proliferate in the shadow of soaring public demand. The following visual highlights detailed information on Eli Lilly’s most recent trademark filing from July 24, related to pharmaceutical preparations targeting obesity treatment.
